Evidence map›Paper›PMID 39474579›Full record

ArticleWorld journal of hepatology2024

Liver cell cancer surveillance practice in Nigeria: Pitfalls and future prospects.

Yusuf Musa, Ijeoma M Ifeorah, Abubakar Sadiq Maiyaki, Rahama Mohammad Almustapha, Yussuf Abdulkadir Maisuna, Habib Tijjani Saleh, Abdulmumini Yakubu

Abstract readEditorial
In one paragraph

Article in World journal of hepatology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yusuf MusaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Federal Teaching Hospital Katsina, Katsina 820101, Nigeria. yusuf.musa@npmcn.edu.ng.
Ijeoma M IfeorahDepartment of Medical Laboratory Sciences, College of Medicine University of Nigeria Enugu Campus, Enugu 400102, Nigeria.
Abubakar Sadiq MaiyakiDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Faculty of Clinical Sciences, College of Health Sciences, Usmanu Danfodiyo University, Sokoto 840283, Nigeria.
Rahama Mohammad AlmustaphaInfection Prevention and Control Unit, Department of Community Medicine, Federal Teaching Hospital, Katsina 820101, Katsina, Nigeria.
Yussuf Abdulkadir MaisunaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Bayero University Kano, Kano 700101, Nigeria.
Habib Tijjani SalehDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Federal Teaching Hospital Katsina, Katsina 820101, Nigeria.
Abdulmumini YakubuDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Usmanu Danfodiyo University, Sokoto 840283, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a disease of public health concern in Nigeria, with chronic hepatitis B and C infections contributing most to the disease burden. Despite the increasing incidence of HCC, surveillance practices for early diagnosis and possible cure are not deeply rooted in the country. This article aims to review the current status of HCC surveillance in Nigeria, stressing the encounters, breaches, and potential prospects. Several factors, such as limited tools for screening and diagnostics, insufficient infrastructure, and low cognizance among the doctors, and the general public affect the surveillance practices for HCC in Nigeria. Moreover, the lack of standardized guidelines and protocols for HCC surveillance further intensifies the suboptimal diagnosis and treatment. Nevertheless, there are opportunities for refining surveillance practices in the country. This would be achieved through boosted public health sensitization campaigns, integrating HCC screening into routine clinical services, and leveraging technological developments for early detection and monitoring. Furthermore, collaboration between government agencies, healthcare providers, and international organizations can facilitate the development of comprehensive HCC surveillance programs personalized to the Nigerian setting. Thus, HCC surveillance practice faces substantial challenges. By addressing the drawbacks and leveraging prospects, Nigeria can improve HCC surveillance, with subsequent improved outcomes for individuals at risk of developing the disease.

Indexed as

Advance diseaseAlpha-fetoproteinDes-gamma-carboxy prothrombinEarly diseaseHepatocellular cancerIntermediate diseaseLate diseaseSurveillanceUltrasonography

Identifiers

PMID39474579
PMCPMC11514613

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.